Theranexus (XPAR:ALTHX) Gross-Profit-to-Asset % : -67.87% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Theranexus Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Theranexus's annualized Gross Profit for the quarter that ended in Dec. 2023 was €-5.16 Mil. Theranexus's average Total Assets over the quarter that ended in Dec. 2023 was €7.61 Mil. Therefore, Theranexus's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was -67.87%.

Theranexus Gross-Profit-to-Asset % Historical Data

The historical data trend for Theranexus's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theranexus Gross-Profit-to-Asset % Chart

Theranexus Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

-31.71

-21.73

-32.33

-27.12

-52.23

Theranexus Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial												-29.20	-23.78	-28.66	-49.07	-67.87

Competitive Comparison of Theranexus's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Theranexus's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theranexus's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theranexus's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Theranexus's Gross-Profit-to-Asset % falls into.

Theranexus Gross-Profit-to-Asset % Calculation

Theranexus's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	-5.038	/	( (12.054	+	7.238)	/ 2 )
	=	-5.038	/	9.646
	=	-52.23 %

Theranexus's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-5.162	/	( (7.974	+	7.238)	/ 2 )
	=	-5.162	/	7.606
	=	-67.87 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Theranexus Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Theranexus's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Theranexus (XPAR:ALTHX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theranexus SA (XPAR:ALTHX) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

3VG:Germany

Address

60 avenue Rockefeller, Pepiniere Laennec, Lyon, FRA, 69008

Website

https://www.theranexus.com

Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.

Theranexus (XPAR:ALTHX) Headlines

No Headlines